FRANKLIN: BD (Becton, Dickinson and Company) global medical technology company, recently announced the U.S. Food and Drug Administration has granted premarket approval for the Venovo venous stent, the first stent indicated to treat iliofemoral venous occlusive disease, which is obstructed or narrowed blood flow specific to the iliac and femoral veins located near the groin.
The Venovo venous stent is a flexible nitinol stent specifically designed to reopen blocked iliac and femoral veins in order to maintain adequate blood flow. The Venovo venous stent is designed with a balance of radial strength, compression resistance and flexibility needed for the treatment of symptomatic post-thrombotic and non-thrombotic iliofemoral lesions. Additionally, the broad stent sizing allows clinicians to treat large diameter veins and long lesion lengths.
“The unique attributes of the Venovo stent make it particularly well-suited to treat iliofemoral occlusive disease,” said Dr Michael Dake, the University of Arizona and the principal investigator for the Venovo IDE trial.
“Most importantly, it is purpose-built for application in veins, and engineered to address the special challenges of venous lesions that are very different than those posed by arterial narrowing,” he added.
The iliofemoral venous occlusive disease occurs when there is impaired blood flow in the iliofemoral vein caused by acute or chronic deep-vein thrombosis, post-thrombotic syndrome, iliofemoral vein compression including May-Thurner Syndrome or a combination of these diseases. Symptoms include swelling of the legs, pain when standing, skin discolouration and ulcers.
One-year results from the prospective, multicenter single-arm VERNACULAR trial involving 170 subjects demonstrated the safety and effectiveness of the Venovo venous stent for the treatment of symptomatic iliofemoral venous outflow obstruction. The clinical findings showed a weighted primary patency rate of 88.3 per cent, with a 96.9 per cent patency rate in non-thrombotic lesions and an 81.3 per cent patency rate in post-thrombotic lesions at 12 months, exceeding the performance goal of 74 per cent.
In addition, patients treated with the Venovo venous stent reported a statistically significant reduction in pain symptoms and improvement in the quality of life (assessed by CIVIQ-20) at 12 months from baseline. The Venovo™ venous stent was also deployed successfully to the target lesion and showed adequate coverage in all cases, and there were no fractures seen at 12 months.
“The FDA premarket approval of the Venovo venous stent represents a significant advance for interventionalists treating iliofemoral venous occlusive disease, an underrecognized condition,” said Steve Williamson, worldwide president of Peripheral Intervention at BD.
“We designed the Venovo venous stent in collaboration with clinicians to enable them to treat both post-thrombotic and non-thrombotic lesions. Clinicians will now have access to the broadest range of stent sizes in the U.S. for these difficult-to-treat lesions,” he added.
The Venovo venous stent is commercially available in the U.S., Europe, Argentina, Australia, Brazil, Egypt, India, Israel, Mexico, Russia, Saudi Arabia, Singapore and Taiwan.